Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03) Meeting Abstract
| Authors: | Janjigian, Y. Y.; Raoufmoghaddam, S.; Sztachelska, M.; Winter, M.; Das, S. |
| Abstract Title: | Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03) |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Keywords: | 298-145-222-184-1022-9126; 261-566-148; 613-213-2711-3371; 261-492-2769; 283-2511; 298-145-222-184-1022-9124; 298-145-222-184-1022-9122 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500364 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.TPS424 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS424 -- Source: Wos |
